

RECORD OF IMMUNIZATIONS FOLLOWING ADULT CAR-T CELL THERAPY

Patient Name: _____

Date of Birth: _____

PHIN: _____

Date of CAR-T: _____

Month 0 = _____

(MM/YY)

Approximate timing after CAR-T	≥ 3 months after CAR-T " Month 0 "	≥ 4 months after CAR-T " Month 1 "	≥ 6 months after CAR-T " Month 3 "	≥ 7 months after CAR-T " Month 4 "	≥ 8 months after CAR-T " Month 5 "	≥ 12 months after CAR-T " Month 9 "	≥ 18 months after CAR-T " Month 15 "	≥ 21 months after CAR-T " Moth 18 "
COVID-19 ¹	MM/ DD / YY	MM/ DD / YY	MM/ DD / YY					
Pneu-C-20 (Pneumococcal conjugate)			MM/ DD / YY	MM/ DD / YY	MM/ DD / YY		MM/ DD / YY	
DTaP-IPV-Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio, haemophilus influenzae type B) ²			MM/ DD / YY		MM/ DD / YY	MM/ DD / YY		
Men-C-ACYW -135 (Meningococcal conjugate)			MM/ DD / YY					
HA (Hepatitis A) (Havrix®1440 Adult)			MM/ DD / YY			MM/ DD / YY		
HB (Hepatitis B) ³ (Engerix-B® 40 mcg dose = 2 mL of 20 mcg/mL = 2 syringes)			MM/ DD / YY	MM/ DD / YY		MM/ DD / YY		
HPV-9 (Human Papillomavirus 9-valent) ⁴ 9 years to 45 years of age inclusive (Gardasil®9)			MM/ DD / YY		MM/ DD / YY	MM/ DD / YY		
MMR (Measles, mumps, rubella) ^{5 6 7}	Live Vaccines – please see bullet point ^{4 5} for initiation criteria						MM/ DD / YY	MM/ DD / YY
Var (Varicella) ^{5 6 8} (Varivax III®)							MM/ DD / YY	MM/ DD / YY
Influenza (inactivated)	Lifelong seasonal administration starting 3 months after date of CAR-T – Individuals > 65 y.o. should receive <u>high-dose influenza vaccine</u>							
Td (Tetanus, diphtheria)	Every 10 years for continued protection							

¹ Regardless of pre-CAR-T immunization status, individuals should have primary series of COVID-19 vaccine post CAR-T. Following completion of the primary series, refer to Manitoba Health’s COVID-19 Vaccine Eligibility web page for current recommendations for additional doses or booster doses.

² Use of pediatric formulation DTaP-IPV-Hib in adults is off-license and is based on expert opinion from the adult CAR-T program

³ Post-vaccination testing for antibody to hepatitis B surface antigen is recommended 1-2 months after the 3rd dose to ensure protection. If anti-HBs are “negative” or “low”, provide an additional 3 doses of hepatitis B vaccine again using the higher dose 40 mcg/dose schedule. Retest anti-HBs one month after the second series of hepatitis B vaccine. If anti-HBs remain “negative” or “low”, consider as non-responder and susceptible to hepatitis B.

⁴ The extended age qualification to 46 years for males is based on expert opinion from the CAR-T program and differs from Manitoba Immunization Guidelines

⁵ Administer **only if off all immunosuppressive therapy for at least 3 months and no ongoing anticancer therapy.**

⁶ Interval between IVIG and a live vaccine is dependent upon the dose of IVIG used and ranges between seven and eleven months. Refer to the Canadian Immunization Guide - [Blood products, human immunoglobulin and timing of immunization: Canadian Immunization Guide - Canada.ca](#)

⁷ Serological testing post 2nd dose of MMR. If measles antibody is not detected, no further doses of vaccine should be administered. The individual would be offered immune globulin on subsequent exposure to wild-type measles. If rubella antibody is not detected, no further doses of vaccine should be administered. The individual would be considered non-immune to rubella. Mumps immunity screening is not recommended.

⁸ Varicella vaccine may be administered during the same visit but at a separate injection site as MMR vaccine. If not given during the same visit as other live virus vaccine (MMR), administration of the two live vaccines should be separated by at least 4 weeks

****ALL VACCINES LISTED ABOVE ARE PROVIDED FREE OF CHARGE BY MANITOBA HEALTH AND OBTAINED FROM THE PROVINCIAL VACCINE WAREHOUSE ****

When administering vaccines, follow contraindications and routine precautions for immunizations as stated in the current version for the Canadian Immunization Guide and the supplementary National Advisory Committee on Immunization Statements online: <http://phac-aspc.gc.ca/naci-ccni/index-eng.php>. For further information or assistance regarding immunization of patients after CAR-t therapy, contact the Adult Clinical Nurse Specialist: (204) 787-1864 or Pharmacist: (204) 787-4493 for product or schedule related questions. Product substitution not recommended